Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Dolutegravir sodium

Dolutegravir sodium synthesis

11synthesis methods
The most likely process-scale synthesis of dolutegravir sodium, began with benzyl protection and alkylation of pyrone 46 with benzaldehyde, yielding alcohol 47 in 74% over 2 steps. Alcohol mesylation and in situ elimination provided the styrenyl olefin 48 in 94% yield, which further underwent an oxidative cleavage of the olefin to generate 49 by sequential addition of RuCl3/NaIO4 and NaClO2 (56% overall yield). Treatment of pyranone 49 with 3-amino-propane-2-diol (50) in ethanol at elevated temperatures delivered the corresponding pyridinone in 83% yield, and this was followed by esterification and sodium periodate-mediated diol cleavage to furnish intermediate 51 in 71% overall yield across the two-step sequence. l Next, the key ring-forming step in the synthesis of dolutegravir sodium consisted of cyclization of 51 with (R)-3- amino-butan-1-ol, a process which relies on substrate control to provide the desired tricyclic carbamoylpyridone system 52 in high stereoselectivity (20/1 in favor of the desired isomer).51 Previously, cyclization of systems such as 51 with unsubstituted amino alcohols were found to yield a mixture of diastereomeric products, therefore indicating the pivotal role of the chiral amino alcohol in influencing stereochemical bias during the overall cyclization step. In practice, reaction of 51 with (R)-3-amino-butan-1-ol at 90 ℃ led to isolation of a single cyclization product 52, after recrystallization from EtOAc. From 52, N-bromosuccinimide (NBS) bromination and subsequent treatment with amine 53 under palladium-catalyzed amidocarbonylative conditions led to amide 54 in 75% yield over 2 steps. Finally, removal of the benzyl group and subsequent crystallization using sodium hydroxide in water and ethanol provided dolutegravir sodium (VII) in 99% yield.

1206102-11-5 Synthesis
(4R,12aS)-N-(2,4-difluorobenzyl)-7-benzylhydroxy-4-Methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxaMide

1206102-11-5
84 suppliers
inquiry

Dolutegravir sodium

1051375-19-9
216 suppliers
inquiry

-

Yield:1051375-19-9 98.9%

Reaction Conditions:

Stage #1: (4R,12aS)-7-(benzyloxy)-N-(2,4-difluorobenzyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2’:4,5]-pyrazino[2,1-b][1,3]oxazine-9-carboxamidewith propylene glycol;palladium 10% on activated carbon;hydrogen at 50;
Stage #2: with sodium t-butanolate at 30 - 70;Temperature;

Steps:

4b Example 4 (General Procedure) Examples 4a, 4b, 4d and 4e: 1 .00 g (1 .96 mmol)

General procedure: Example 4 (General Procedure) Examples 4a, 4b, 4d and 4e: 1 .00 g (1 .96 mmol) DTG-OBn was suspended in 10 mL racemic 1 ,2-PG and 5 mL of a co-solvent. The flask was flushed with argon and then charged with 42 mg of 10% palladium on activated charcoal (50% wet, 0.20 mmol, 0.01 eq.). The resulting mixture was heated to 50 °C and stirred under hydrogen atmosphere until completion. The flask was flushed with argon and the warm mixture was filtered over glass fiber filter. The filtrate was charged into a clean flask and heated to the desired temperature (see Table below). A solution of 192 mg (1 .96 mmol, 1 .0 eq.) sodium tert-butylate in 2 ml. racemic 1 ,2-PG was added to the mixture, under vigorous stirring. After completion of the addition, a clear yellow solution was obtained. A solid started to precipitate within 5 min. After stirring for 5-15 min, the heating of the oil bath was turned off and after 90 min (T (oil bath) = approx. 30°C), the oil bath was removed, the mixture was stirred for another 30 min at RT and then filtered. The isolated solid was washed with acetone and dried at 50°C under vacuum (10 mbar) for different times (see table) yielding Dolutegravir sodium salt (1 :1 ) 1 ,2-propylene glycol solvate as off-white solid.

References:

WO2017/46131,2017,A1 Location in patent:Page/Page column 30; 31

1335210-35-9 Synthesis
O-Methyl Dolutegravir

1335210-35-9
78 suppliers
inquiry

Dolutegravir sodium

1051375-19-9
216 suppliers
inquiry

Dolutegravir sodium Related Search: